{"id":778888,"date":"2025-12-10T10:30:02","date_gmt":"2025-12-10T10:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=778888"},"modified":"2025-12-10T10:30:02","modified_gmt":"2025-12-10T10:30:02","slug":"glp1-agonists-market-to-reach-usd-17075-billion-by-2033-driven-by-manufacturing-expansion-indication-growth-and-rising-metabolic-disease-burden","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/glp1-agonists-market-to-reach-usd-17075-billion-by-2033-driven-by-manufacturing-expansion-indication-growth-and-rising-metabolic-disease-burden_778888.html","title":{"rendered":"GLP-1 Agonists Market to Reach USD 170.75 Billion by 2033 Driven by Manufacturing Expansion, Indication Growth, and Rising Metabolic Disease Burden"},"content":{"rendered":"
\n
\"GLP-1<\/a><\/div>\n
\n
The market for GLP-1 agonists is highly consolidated, with key players strategizing to capture the market. Prominent players in the GLP-1 agonists market are Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), among other players.<\/div>\n<\/div>\n<\/div>\n
Browse 400 market data Tables and 45 Figures spread through 300 Pages and in-depth TOC on “GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) – Global Forecast to 2033<\/div>\n

The global GLP-1 Agonists Market<\/strong>, valued at US$53.74 billion in 2024<\/strong>, grew to US$64.42 billion in 2025<\/strong> and is projected to surge to US$170.75 billion by 2033<\/strong>, registering a resilient CAGR of 13.0%<\/strong> throughout the forecast period. The unprecedented growth of this market is driven by advancements in manufacturing capacity, expanding therapeutic indications, and the rising global prevalence of obesity and type 2 diabetes (T2D)<\/strong>. As demand accelerates, GLP-1 therapies are transitioning from niche metabolic treatments to mainstream therapeutic solutions across chronic disease management.<\/p>\n

Download PDF Brochure: https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=218746186<\/a><\/strong><\/p>\n

Market Overview: Manufacturing Scale-Up and Therapeutic Expansion Drive Strong Growth<\/strong><\/p>\n

The GLP-1 agonist class—including widely recognized agents such as semaglutide, tirzepatide, and liraglutide—has entered a period of explosive global demand. To address supply shortages and meet rising prescription volumes, pharmaceutical companies are significantly expanding both API production and fill-finish capabilities<\/strong>. These investments are enhancing global supply chain resilience and improving product accessibility across high-growth markets.<\/p>\n

Simultaneously, indication expansion<\/strong> is reshaping the competitive landscape. Beyond traditional diabetes applications, GLP-1 therapies are gaining regulatory approvals for obesity, cardiovascular risk reduction, non-alcoholic steatohepatitis (NASH), and metabolic comorbidities<\/strong>. This wider clinical applicability is increasing physician adoption and strengthening the long-term growth trajectory of the market.<\/p>\n

Additionally, the global epidemic of obesity and type 2 diabetes continues to intensify. According to major international health agencies, obesity rates have more than doubled in many countries over the last three decades, placing immense pressure on healthcare systems. GLP-1 agonists—proven to improve glycemic control, induce weight loss, and confer cardiometabolic benefits—are emerging as frontline treatment options in clinical practice.<\/p>\n

Comprehensive Market Coverage<\/strong><\/p>\n

Browse in-depth TOC on “GLP-1 Analogues Market”:<\/strong><\/p>\n